SARS-CoV-2 Neutralizing Antibody Biotinylated

Product Description

SARS-CoV-2 Neutralizing Antibody Biotinylated
Catalog number: B2010706
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 50 ug
Molecular Weight or Concentration: na
Supplied as: Solution
Applications: versatile molecular tool in the research and development of assays involving SARS-CoV-2
Storage: -20C
Keywords: Spike Neutralizing Antibody biotin, Spike Neutralizing Antiody-biotin
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Barnes CO, Jette CA, Abernathy ME, Dam KA, Esswein SR, Gristick HB, Malyutin AG, Sharaf NG, Huey-Tubman KE, Lee YE, Robbiani DF, Nussenzweig MC, West AP Jr, Bjorkman PJ. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies Nature. 2020 Dec;588(7839):682-687.
2: Tuccori M, Ferraro S, Convertino I, Cappello E, Valdiserra G, Blandizzi C, Maggi F, Focosi D. Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline MAbs. 2020 Jan-Dec;12(1):1854149.
3: Kim C, Ryu DK, Lee J, Kim YI, Seo JM, Kim YG, Jeong JH, Kim M, Kim JI, Kim P, Bae JS, Shim EY, Lee MS, Kim MS, Noh H, Park GS, Park JS, Son D, An Y, Lee JN, Kwon KS, Lee JY, Lee H, Yang JS, Kim KC, Kim SS, Woo HM, Kim JW, Park MS, Yu KM, Kim SM, Kim EH, Park SJ, Jeong ST, Yu CH, Song Y, Gu SH, Oh H, Koo BS, Hong JJ, Ryu CM, Park WB, Oh MD, Choi YK, Lee SY. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein Nat Commun. 2021 Jan 12;12(1):288.
4: Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, Rigby S, Williams SV, Bermingham WH, Kellam P, Maher J, Shields AM, Amirthalingam G, Peacock SJ, Ismail SA. Antibody response to SARS-CoV-2 infection in humans: A systematic review PLoS One. 2020 Dec 31;15(12):e0244126.
5: Poeschla E. Neutralizing SARS-CoV-2 Elife. 2020 Dec 15;9:e64496.
6: Edara VV, Hudson WH, Xie X, Ahmed R, Suthar MS. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination JAMA. 2021 May 11;325(18):1896-1898.
7: Yuan M, Liu H, Wu NC, Wilson IA. Recognition of the SARS-CoV-2 receptor binding domain by neutralizing antibodies Biochem Biophys Res Commun. 2021 Jan 29;538:192-203.
8: Boehm E, Kronig I, Neher RA, Eckerle I, Vetter P, Kaiser L; Geneva Centre for Emerging Viral Diseases. Novel SARS-CoV-2 variants: the pandemics within the pandemic Clin Microbiol Infect. 2021 Aug;27(8):1109-1117.
9: Zhou G, Zhao Q. Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2 Int J Biol Sci. 2020 Mar 15;16(10):1718-1723.
10: Liu P, Cai J, Jia R, Xia S, Wang X, Cao L, Zeng M, Xu J. Dynamic surveillance of SARS-CoV-2 shedding and neutralizing antibody in children with COVID-19 Emerg Microbes Infect. 2020 Dec;9(1):1254-1258.

Products Related to SARS-CoV-2 Neutralizing Antibody for Wild Type and Variants Biotinylated: Conjugates